Skip to main content

Table 2 Trastuzumab, HER2-targeted therapy, chemotherapy, and endocrine therapy treatments and durations

From: Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)

 

Older patients (> 65)

Younger patients (< 65)

All Patients

Patients, n

1583

3821

5404

Trastuzumab

 Number of trastuzumab courses,a n patients

  One course

1583 (100%)

3821 (100%)

5404 (100%)

  Two courses

319 (20%)

1079 (28%)

1398 (26%)

  Three or more courses

61 (4%)

341 (9%)

402 (7%)

 Median time on all trastuzumab treatment,b months (IQR)

14.1 (5.9–32.1)

18.2 (8.7–40.9)

16.8 (7.8–38.2)

 Median duration of the first uninterrupted course of trastuzumab, months (IQR)

12.1 (4.6–24.9)

14.0 (6.5–28.9)

13.5 (5.9–27.6)

 Trastuzumab monotherapy only, n

154 (10%)

163 (4%)

317 (6%)

HER2-targeted therapies

 Treated with other HER2-targeted therapies for MBC, n:

340 (21%)

1404 (37%)

1744 (32%)

  Lapatinib

182 (11%)

950 (25%)

1132 (21%)

  Pertuzumab

91 (6%)

284 (7%)

375 (7%)

  T-DM1

101 (6%)

300 (8%)

401 (7%)

 Median time on all HER2-targeted therapies,b months (IQR)

15.4 (6.3–37.0)

21.5 (10.1–48.8)

19.4 (8.8–45.0)

 Median proportions of observed survival timec on all HER2-targeted therapies, including trastuzumab, % (IQR)

85% (58–100%)

85% (61–99%)

85% (60–99%)

Chemotherapy

 Dispensed chemotherapy, n

1170 (74%)

3342 (87%)

4512 (83%)

 Median number of unique chemotherapies dispensed per person, n (IQR)

1 (0–2)

2 (1–3)

2 (1–3)

 Median time on all chemotherapy,b months (IQR)

5.6 (3.3–10.8)

8.3 (4.5–16.5)

7.4 (4.2–15.1)

 Median proportion of survival time on chemotherapy, % (IQR)

30% (13–53%)

38% (18–62%)

36% (16–60%)

Endocrine therapy

 Dispensed endocrine therapy, nd

885 (56%)

2179 (57%)

3064 (57%)

 Median time on all endocrine therapy,b,d months (IQR)

14.5 (3.8–41.2)

16.4 (4.9–43.6)

15.8 (4.6–42.6)

 Median proportion of survival time on endocrine therapy, % (IQR)

60% (27–88%)

49% (20–80%)

52% (21–82%)

  1. aA course is defined as consecutive dispensings of trastuzumab closer in time than 90 days. A gap of ≥ 90 days between trastuzumab dispensings was considered a break in trastuzumab therapy and the subsequent dispensing considered the start of a new course of therapy.
  2. bExcluding breaks in treatment ≥ 90 days
  3. cObserved duration of treatment, excluding breaks, as a proportion of observed survival time from initiation of trastuzumab for MBC
  4. dOnly endocrine therapies dispensed between 30 days prior to initiating trastuzumab for MBC and death or censor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us